-+ 0.00%
-+ 0.00%
-+ 0.00%

SELLAS Life Sciences Group Stock After Phase 3 Win And $150 Million Share Sale

Simply Wall St·11/20/2026 11:12:27
Listen to the news
  • SELLAS Life Sciences Group reported positive topline Phase 3 REGAL data for its AML vaccine galinpepimut-S and, soon after, completed a US$150.0 million follow on equity offering of 11,538,462 common shares at US$13, a US$0.78 per share discount.
  • The capital raise, coming immediately after a pivotal survival readout, highlights both the cash needs of late stage oncology development and the funding SELLAS Life Sciences Group is securing to prepare for a potential GPS launch.
  • We will now look at how SELLAS Life Sciences Group’s investment narrative is reshaped by the Phase 3 success and rapid equity financing.
Spot 36 healthcare AI stocks that, like SELLAS Life Sciences Group, are using next generation therapies and data driven research to push the edge of what biotech can do for patients.

SELLAS Life Sciences Group Investment Narrative Recap

To own SELLAS Life Sciences Group, you need to be comfortable with a single asset driving most of the story and no current product revenue. The big near term catalyst is GPS moving from positive Phase 3 data into a clear regulatory path and launch plan. The recent US$150.0m equity raise supports operations and launch preparation but adds dilution risk on top of an already loss making profile.

The analyst consensus narrative on Simply Wall St hinges on GPS and SLS009 progressing while funding keeps up with burn. In the near term, the biggest operating risk is any legal or disclosure issue around REGAL or GPS that could slow regulatory timelines. Heavy reliance on equity markets also remains a central concern for current shareholders.

The completed US$150.0m follow on offering at US$13 per share, at a discount to the last close, is the most relevant announcement for this phase. That cash pool gives SELLAS Life Sciences Group more room to execute on GPS regulatory work, manufacturing scale up and commercial readiness, while continuing SLS009 trials without reported revenue support.

For you as an investor, that financing cuts both ways. Liquidity and runway improve, which reduces one operational overhang. However, the share sale adds to a history of dilution and a high P/B multiple. Future catalysts now depend on clear FDA feedback on GPS, progress on the Biologics License Application work toward 2027, updates on SLS009 and any developments in the short swing trading complaint or other legal matters.

SELLAS Life Sciences Group's current narrative centers on analysts projecting revenue of US$158.9 million and earnings of US$48.5 million by 2029, increasing from no revenue today and an earnings loss of US$35.8 million. This change implies a very large earnings swing of roughly US$84 million if those forecasts are met.

Uncover why SELLAS Life Sciences Group's fair value indicates a 152% potential upside to its current price that could narrow quickly.

NasdaqCM:SLS 1-Year Stock Price Chart
NasdaqCM:SLS 1-Year Stock Price Chart

Exploring Other Perspectives

Fair value estimates for SELLAS Life Sciences Group from 2 members of the Simply Wall St Community cluster at US$37.50, well above the recent US$13 offering price. You are weighing those optimistic models against legal and dilution risks around equity funding and disclosure scrutiny, so it pays to compare several sharply different views.

Explore another SELLAS Life Sciences Group fair value estimate, including one that suggests it could be worth just $37.50!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more investment ideas beyond SELLAS Life Sciences Group?

Once you have formed a view on SELLAS Life Sciences Group, it often helps to compare it with other companies that fit clear, rules based filters. The Simply Wall St Screener can help you quickly surface a wider watchlist that matches the kind of opportunities you want to focus on next.